MCKESSON CORPMCK

時価総額
$1027.1億
PER
医療サービスと医薬品流通の米国最大手。アウトペイシェント、リテール、スペシャリティ薬局とオンコロジー向けの処方箋技術やデータ解析を展開。2025年3月期に最大顧客向け売上が約24%、2022年11月に処方箋価格透明サービスの同業を100%で買収。米国中心にカナダとノルウェーで展開。
2010年
3月31日
2011年
3月31日
2012年
3月31日
2013年
3月31日
2014年
3月31日
2015年
3月31日
2016年
3月31日
2017年
3月31日
2018年
3月31日
2019年
3月31日
2020年
3月31日
2021年
3月31日
2022年
3月31日
2023年
3月31日
2024年
3月31日
2025年
3月31日
Net income----1,2581,5432,3105,1532972551,120-4,3401,2873,7223,1603,481
Depreciation148139140146186306281324303317321321279248253242
Amortization326357411445518711604586648632601566481360382394
Other Asset Impairment Charges------------175724398
Deferred taxes----606-16-171-64-882868-189342908-3420603110
Inventory, LIFO Reserve, Period Charge----311337244-7-99-210-252-38-231-15782
Operating Lease, Expense----------366334241249228245
Loss (gain) from sales of businesses and investments-----------33913221117-485
Provision for bad debts17183028----------819-130
Other non-cash items---66-56-130-47-108-882-52-615-188-501-298-233-424
Receivables-133673770-3268852,8211,957762-1,1759672,494-1,1451,8431,0822,9543,935
Inventories-782-367878591,2012,1441,251-3204583683762,2761,1691,2591,2942,270
Drafts and accounts payable1,3405332,027-1252,4124,7183,3022,0702711,9763,9521,2672,8023,7884,5878,301
Operating lease liabilities-------------356-338-339-404
Taxes----80218-222-78146671-95-8-166243363331-136
Litigation liabilities-----------8,067199-1,088-395-401
Other21144149-86-42-137365-222-688-511-206-56-37281
Net cash provided by operating activities2,3162,3382,9502,4833,1363,1123,6724,7444,3454,0364,3744,5424,4345,1594,3146,085
Payments for property, plant, and equipment199233225246274376488404405426362451388390431537
Capitalized software expenditures---160141169189158175131144190147168256322
Acquisitions, net of cash, cash equivalents, and restricted cash acquired182921,1561,8734,634170404,2372,89390513335686727224
Proceeds from sales of businesses and investments, net------210206-101--5781,07747179
Other-3153-89-3894-23111-751820-2313912619416029
Net cash used in investing activities-309-624-1,502-2,209-5,046-677-1,557-3,796-1,522-1,381-579-415-89-542-1,072-733
Proceeds from Short-Term Debt51,0004002,2256,1453,1001,5618,29420,54237,26521,4376,32311,1928,45019,96415,086
Repayments of short-term borrowings6-1,000-2,6256,1223,1521,6888,12420,72537,26821,4376,32311,1928,45019,96415,086
Proceeds from Issuance of Long-Term Debt-1,689-1,7984,1143-1,8241,5221,099-500498997991498
Repayments of long-term debt218-1,7304301,1433563531,5981,6012,2871,1122981,0401,6481,274288519
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt--------------647-
Issuances---1661771521231201327511392220163116101
Share repurchases--1,8741,2141304501,6122,3111,7091,6391,9547703,5163,6383,0253,146
Dividends paid--195194214227244253262292294276277292314345
Other405427315-415-18-185-355-301-199-383-324-175-554
Net cash used in financing activities-421-1,841-1,905-9563,619-968-3,453-2,069-3,084-2,227-2,734-1,693-6,321-4,368-3,342-3,965
Effect of exchange rate changes on cash, cash equivalents, and restricted cash----------119-19-6155256-16
Cash, cash equivalents, and restricted cash classified as Assets held for sale-------------540470--
Net increase (decrease) in cash, cash equivalents, and restricted cash---------3091,0422,373-2,461744-941,371
Interest, net188244228------383235220186224234273
Income Taxes Paid, Net234347337555088669235871442623683793595629011,124